Remove 2014 Remove Licensing Remove Regulations
article thumbnail

Article FDA Thank You New FDA guidance on addressing misinformation under White House review

Agency IQ

New FDA guidance on addressing misinformation under White House review A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA).

FDA 40
article thumbnail

Article FDA Thank You FDA draft guidance on addressing misinformation clears White House review

Agency IQ

FDA draft guidance on addressing misinformation clears White House review A few months ahead of a potential administration transition, the White House has cleared (with changes) a new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You FDA gives companies leeway to go after misinformation, but not free reign

Agency IQ

While the policy is similar in some respects to one first created by the FDA in 2014, the latest version is considerably more detailed regarding what it will – and won’t – allow companies to do. BY LAURA DIANGELO, MPH | JUL 10, 2024 3:47 PM CDT Regulatory background: The FDA is responsible for overseeing information about regulated products.

FDA 40
article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

Improvements in technology and changes to worldwide regulations in life sciences has led to an increase in the availability of clinical data. Remote trials, wearable devices and advancements in genomic sequencing means that clinical data is now more abundant than ever and is only set to grow. .

article thumbnail

How Pharma-Funded Groups Lie About Personal Drug Imports

Policy Prescription

Most of that writing was on PharmacyCheckerBlog – but periodically it shows up in national media, including in the New York Times back in 2014, and more recently this past February The Hill. and licensed by your state board of pharmacy.” state-licensed board of pharmacy licensed pharmacy.”. Emphasis added).

article thumbnail

Etrasimod

New Drug Approvals

2014, 5, 12, 1313–1317 Publication Date:November 4, 2014 [link] APD334 was discovered as part of our internal effort to identify potent, centrally available, functional antagonists of the S1P 1 receptor for use as next generation therapeutics for treating multiple sclerosis (MS) and other autoimmune diseases. . 11] SYN ACS Med.

FDA 57
article thumbnail

Hemogenyx Pharmaceuticals PLC Announces Update on CDX Antibody Development

The Pharma Data

With the phase of the Agreement relating to the development of the antibody completed, under the Agreement, as of 11 January 2021, GlobalCo has three months to exercise an option to license the Company’s intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis (“Option”). .